{
    "Trade/Device Name(s)": [
        "DEKA Loop"
    ],
    "Submitter Information": "DEKA Research & Development",
    "510(k) Number": "K234055",
    "Predicate Device Reference 510(k) Number(s)": [
        "K203689"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QJI"
    ],
    "Summary Letter Date": "March 13, 2024",
    "Summary Letter Received Date": "December 22, 2023",
    "Submission Date": "February 29, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1356"
    ],
    "Regulation Name(s)": [
        "Interoperable Automated Glycemic Controller"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DEKA ACE Pump System",
        "iPhone (for app interface)",
        "Compatible integrated continuous glucose monitor (iCGM)",
        "Alternate Controller Enabled (ACE) insulin infusion pump"
    ],
    "Method(s)/Technology(ies)": [
        "Hybrid closed loop predictive control algorithm",
        "Software as a Medical Device (SaMD)"
    ],
    "Methodologies": [
        "Predictive glucose monitoring",
        "Insulin delivery algorithm"
    ],
    "Submission Type(s)": [
        "Software",
        "System",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for DEKA Loop interoperable automated glycemic controller software for automated insulin delivery with compatible iCGM and ACE pumps.",
    "Indications for Use Summary": "Intended for management of type 1 diabetes mellitus in persons six years and older using compatible integrated CGMs and ACE pumps to automatically adjust basal insulin and recommend/deliver correction boluses when glucose is predicted to exceed configurable thresholds; single patient use, prescription only.",
    "fda_folder": "Clinical Chemistry"
}